Hypertrophic cardiomyopathy: diagnosis, risk stratification and strategies to prevent sudden cardiac death
- Authors: Steklov V.I.1,2, Morozova N.V.1, Ivanov S.А.3, Gmir Т.N.3
-
Affiliations:
- The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
- Branch of the S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
- 12 Consultative and Diagnostic Center of the Russian Defense Ministry
- Issue: Vol 345, No 1 (2024)
- Pages: 39-49
- Section: Treatment and prophylactic issues
- URL: https://journals.eco-vector.com/0026-9050/article/view/627334
- DOI: https://doi.org/10.52424/00269050_2024_345_1_39
- ID: 627334
Cite item
Abstract
Hypertrophic cardiomyopathy is the most common cause of sudden cardiac death in young adults, including athletes. The article highlights modern ideas about this hereditary disease. At the modern level, the most important issues of the etiology and pathogenesis of the disease, as well as the primary methods of its diagnosis, are considered. The authors paid much attention to differential diagnosis and clinical variants of the disease. It outlined modern models of risk stratification and an algorithm for the prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. This algorithm is designed to identify patients at high risk of sudden cardiac death. Currently, implantable cardioverter-defibrillator therapy is the most significant innovative technology that has changed the natural history of hypertrophic cardiomyopathy in many patients and given them decades of productive life.
Full Text
About the authors
V. I. Steklov
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation; Branch of the S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Author for correspondence.
Email: vsteklov@yandex.ru
заслуженный врач РФ, доктор медицинских наук, доцент, полковник медицинской службы запаса
Russian Federation, Moscow; MoscowN. V. Morozova
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: vsteklov@yandex.ru
Russian Federation, Moscow
S. А. Ivanov
12 Consultative and Diagnostic Center of the Russian Defense Ministry
Email: vsteklov@yandex.ru
подполковник медицинской службы запаса
Russian Federation, MoscowТ. N. Gmir
12 Consultative and Diagnostic Center of the Russian Defense Ministry
Email: vsteklov@yandex.ru
Russian Federation, Moscow
References
- Велиева Л.М., Джорджикия Р.К. Обструктивная гипертрофическая кардиомиопатия: исторические аспекты и современные методы лечения // Вестн. современной клин. мед. – 2020. – Т. 13, № 2. – С. 55–62.
- Габрусенко С.А., Гудкова А.Я., Козиолова Н.А. и др. Гипертрофическая кардиомиопатия. Клинические рекомендации 2020 // Рос. кардиол. журн. – 2021. – № 5. – С. 269–334.
- Голухова Е З., Громова О.И., Булаева Н.И. и др. Внезапная сердечная смерть у больных ишемической болезнью сердца: от механизмов к клинической практике // Кардиология. – 2017. – Т. 57, № 12. – С. 73–81.
- Каплунова В.Ю., Шакарьянц Г.А., Кожевникова М.В. и др. Современные подходы к проблеме гипертрофической кардиомиопатии // Клин. мед. – 2016. – Т. 94, № 10. – С. 754–763.
- Полякова А.А., Гудкова А Я., Крутиков А.Н. и др. Гипертрофическая кардиомиопатия в старшей возрастной группе: влияние факторов кардиометаболического риска и полиморфизма гена MADD // Артериальная гипертензия. – 2018. – Т. 24, № 1. – С. 29–40.
- Резник Е.В., Нгуен Т.Л., Дикаева М.С. и др. Особенности диагностики и течения гипертрофической кардиомиопатии в реальной клинической практике // Архивъ внутренней мед. – 2023. – Т. 13. – № 3. – С. 181–195.
- Шилова М.А. Внезапная сердечная смерть лиц молодого возраста: факторы риска, причины, морфологические эквиваленты // Междунар. журн. сердца и сосудистых заболеваний. – 2015. – Т. 3, № 6. – С. 25–34.
- Desai M., Mentias A. Risk stratification in hypertrophic cardiomyopathy // Aging (Albany NY). – 2019. – Vol. 11, N 6. – P. 1617–1618.
- Elliott P., Anastasakis A., Borger M. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology // E. Heart J. – 2014. – Vol. 35, N 39. – P. 2733–2779.
- Finocchiaro G., Magavern E., Sinagra G. et al. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy // J. Am. Heart Assoc. – 2017. – Vol. 6, N 12. – P. e007161.
- Foа A., Agostini V., Rapezzi C. et al. Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy // Int. J. Cardiol. – 2019. – Vol. 291, N 9. – P. 77–82.
- Gersh B., Maron B., Bonow R. et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation. – 2011. – Vol. 124, N 24. – P. e783–e831.
- Geske J.B., Ommen S.R., Gersh B.J. Hypertrophic cardiomyopathy: clinical update // JACC: Heart Failure. – 2018. – Vol. 6, N 5. – P. 364–375.
- Hiemstra Y.L., Debonnaire P., van Zwet E.W. et al. Development of and progression of overt heart failure in nonobstructive hypertrophic cardiomyopathy // Am. J. Cardiol. – 2018. – Vol. 122, N 4. – P. 656–662.
- Huang X., Yue Y., Wang Y., et al. Assessment of left ventricular systolic and diastolic abnormalities in patients with hypertrophic cardiomyopathy using real-time three-dimensional echocardiography and two-dimensional speckle tracking imaging // Cardiovasc. Ultrasound. – 2018. – Vol. 16, N 1. – P. 23.
- Jaaskelainen P., Vangipurapu J., Raivo J. et al. Genetic basis and outcome in a nationwide study of Finnish patients with hypertrophic cardiomyopathy // ESC Heart Failure. – 2019. – Vol. 6, N 2. – P. 436–445.
- Liebregts M., Faber L., Jensen M. et al. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation // Europace. – 2018. – Vol. 20, N FI2. – P. f198–f203.
- Manabe S., Kasegawa H., Arai H. et al. Management of systolic anterior motion of the mitral valve: a mechanism-based approach // Gen. Thorac. Cardiovasc. Surg. – 2018. – Vol. 66. – P. 379–389.
- Maron B.J., Casey S.A., Chan R.H. et al. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy // Am. J. Cardiol. – 2015. – Vol. 116, N 5. – P. 757–764.
- Maron B.J., Rowin E.J., Casey S.A. et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age // Circulation. – 2013. – Vol. 127, N 5. – P. 585–593.
- Morimoto R., Ito R., Araki T. et al. Contractile pericarditis-like hemodynamics in dilated-phase hypertrophic cardiomyopathy with giant atrium // J. of Cardiol. Cases. – 2023. – Vol. 27, N 5. – P. 199–202.
- Mitchell C., Rahko P.S., Blauwet L.A. et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography // J. Am. Soc. Echocardiogr. – 2019. – Vol. 32, N 1. – P. 1–64.
- Olivotto I., Cecchi F., Poggesi C. et al. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging // Circ. Heart Fail. – 2012. – Vol. 5, N 4. – P. 535–546.
- Pelliccia A., Solberg E., Papadakis M. et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC) // Eur. Heart J. – 2019. – Vol. 40, N 1. – P. 19–33.
- Rodrigues J.C., Amadu A.M., Dastidar A.G. et al. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance // Eur. Heart J. Cardiovasc. Imaging. – 2015. – Vol. 17, Iss. 12. – P. 1405–1413.
- Shiozaki A., Senra T., Arteaga E. et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy // J. Cardiovasc. Comput. Tomogr. – 2013. – Vol. 7, N 3. – P. 173–181.
- Teare D. Asymmetrical hypertrophy of the heart in young adults // Br. Heart J. – 1958. – Vol. 20, N 1. – P. 1–8.